Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

99% OF PATIENTS GOT TO T GOAL BY DAY 7

FIRMAGON®
HELPED 52% OF PATIENTS REACH CASTRATE LEVELS (T ≤50 ng/dL)
ON DAY 11,2

PERCENTAGE OF
PATIENTS
ACHIEVING
CASTRATE LEVELS1*

Half of Firmagon® patients reached castrate level goals on day 1
Half of Firmagon® patients reached castrate level goals on day 1 Half of Firmagon® patients reached castrate level goals on day 1 Half of Firmagon® patients reached castrate level goals on day 1 Half of Firmagon® patients reached castrate level goals on day 1 Half of Firmagon® patients reached castrate level goals on day 1

Study Design

The pivotal phase 3 trial (CS21) was a 3-armed, randomized (1:1:1), active-controlled, open-label, parallel-group, 12-month clinical study of FIRMAGON compared to leuprolide acetate (Lupron Depot®).3 Serum levels of testosterone were measured at screening, on days 0, 1, 3, 7, 14, and 28 in the first month, and then monthly until the end of the study.1

PRIMARY ENDPOINT3:

FIRMAGON was shown to maintain testosterone suppression below castration level (≤50 ng/dL) during 12 months of treatment.

SECONDARY ENDPOINTS3:

  • Proportion of patients with testosterone ≤50 ng/dL
  • Serum levels of testosterone, prostate-specific antigen (PSA), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) over time
  • Percentage change in PSA from baseline

Abbreviations: FSH = follicle-stimulating hormone; LH = luteinizing hormone; PSA = prostate-specific antigen; T = testosterone.

Lupron Depot is a registered trademark of ABBVIE ENDOCRINE INC.

Monthly Matters

Help make the most of your patient's
treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.
Actual physician quote

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.